Galantamine for Alzheimer's disease

Loy, Clement T.; Schneider, Lon S.

doi:10.1002/14651858.cd001747.pub2

Cited by 107 publications

(36 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The causes of this variability are currently unknown. In addition, according to Cochrane reviews [14][15][16], the effect over time of AChEIs is not a long-lasting one: in the AD2000 study [17] the authors did not find any overall significant difference between AD patients treated with donepezil and AD patients treated with placebo after 9 months, the same time-window used in our study. However, it has to be pointed out that the lack of a significant effect in that study could have been due to the heterogeneity of the AD-treated patients as this group may have included both BAD-and GOOD-responders to the treatment.…”

Section: Introductionmentioning

confidence: 54%

GOOD or BAD Responder? Behavioural and Neuroanatomical Markers of Clinical Response to Donepezil in Dementia

Bottini

Berlingeri

Basilico

et al. 2012

Behavioural Neurology

View full text Add to dashboard Cite

Abstract. We explored the neuropsychological and neuromorphometrical differences between probable Alzheimer's disease patients showing a good or a bad response to nine months treatment with donepezil. Before treatment, the neuropsychological profile of the two patient groups was perfectly matched. By the ninth month after treatment, the BAD-responders showed a decline of the MMSE score together with a progressive impairment of executive functions. A voxel-based morphometry investigation (VBM), at the time of the second neuropsychological assessment, showed that the BAD-responders had larger grey and white matter atrophies involving the substantia innominata of Meynert bilaterally, the ventral part of caudate nuclei and the left uncinate fasciculus, brain areas belonging to the cholinergic pathways. A more widespread degeneration of the central cholinergic pathways may explain the lack of donepezil efficacy in those patients not responding to a treatment that operates on the grounds that some degree of endogeneous release of acetylcholine is still available.

show abstract

Section: Introductionmentioning

confidence: 54%

GOOD or BAD Responder? Behavioural and Neuroanatomical Markers of Clinical Response to Donepezil in Dementia

Bottini

Berlingeri

Basilico

et al. 2012

Behavioural Neurology

View full text Add to dashboard Cite

show abstract

“…16 Patients with mild to moderate dementia (Mini-Mental State Examination [MMSE] 17 score of 10-25 inclusive and an ADAS-cog 18 score of at least 18) were eligible. We excluded patients who were in nursing homes, those who had disabling communication difficulties (problems in language, speech, vision or hearing), other active medical issues or competing causes of dementia, patients who had taken anti-dementia medications within 30 days before screening for study enrolment, those who were hypersensitive to cholinomimetic agents or bromide and those who had been in other galantamine trials.…”

Section: Methodsmentioning

confidence: 99%

Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial

Rockwood

Fay²,

Song³

et al. 2006

Canadian Medical Association Journal

139

159

View full text Add to dashboard Cite

“…However, some cases of each of these clinical subtypes have been documented to result from AD and other diseases similar to the pathology of FTLD [24] . This diagnostic challenge is clinically important because some treatments may be effective for some dementias and not others [18,[25][26][27] , and because the prognosis may vary across dementias. Two studies have indicated that the most common pathological finding in SD is ubiquitin-positive inclusions of the motor neuron disease type, even in patients with no clinical evidence of motor neuron disease [28,29] .…”

Section: Introductionmentioning

confidence: 99%

Utility of Behavioral versus Cognitive Measures in Differentiating between Subtypes of Frontotemporal Lobar Degeneration and Alzheimer’s Disease

Heidler‐Gary

Gottesman²,

Newhart

et al. 2007

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

We hypothesized that a modified version of the Frontal Behavioral Inventory (FBI-mod), along with a few cognitive tests, would be clinically useful in distinguishing between clinically defined Alzheimer’s disease (AD) and subtypes of frontotemporal lobar degeneration (FTLD): frontotemporal dementia (dysexecutive type), progressive nonfluent aphasia, and semantic dementia. We studied 80 patients who were diagnosed with AD (n = 30) or FTLD (n = 50), on the basis of a comprehensive neuropsychological battery, imaging, neurological examination, and history. We found significant between-group differences on the FBI-mod, two subtests of the Rey Auditory Verbal Learning Test (verbal learning and delayed recall), and the Trail Making Test Part B (one measure of ‘executive functioning’). AD was characterized by relatively severe impairment in verbal learning, delayed recall, and executive functioning, with relatively normal scores on the FBI-mod. Frontotemporal dementia was characterized by relatively severe impairment on the FBI-mod and executive functioning in the absence of severe impairment in verbal learning and recall. Progressive nonfluent aphasia was characterized by severe impairment in executive functioning with relatively normal scores on verbal learning and recall and FBI-mod. Finally, semantic dementia was characterized by relatively severe deficits in delayed recall, but relatively normal performance on new learning, executive functioning, and on FBI-mod. Discriminant function analysis confirmed that the FBI-mod, in conjunction with the Rey Auditory Verbal Learning Test, and the Trail Making Test Part B categorized the majority of patients as subtypes of FTLD or AD in the same way as a full neuropsychological battery, neurological examination, complete history, and imaging. These tests may be useful for efficient clinical diagnosis, although progressive nonfluent aphasia and semantic dementia are likely to be best distinguished by language tests not included in standard neuropsychological test batteries.

show abstract

Galantamine for Alzheimer's disease

Cited by 107 publications

References 54 publications

GOOD or BAD Responder? Behavioural and Neuroanatomical Markers of Clinical Response to Donepezil in Dementia

GOOD or BAD Responder? Behavioural and Neuroanatomical Markers of Clinical Response to Donepezil in Dementia

Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial

Utility of Behavioral versus Cognitive Measures in Differentiating between Subtypes of Frontotemporal Lobar Degeneration and Alzheimer’s Disease

Contact Info

Product

Resources

About